Clinical

Dataset Information

0

Efficacy exploration of 2nd line in advanced colorectal cancer


ABSTRACT: Interventions: Drug : Registry study Day 1. Aflibercept + FOLFIRI • aflibercept(Zaltrap): 4 mg/kg IV infusion for over 1hr (Do not administer as an IV push or bolus) • Leucovorin: 400 mg/m2 IV infusion for over 2 hours • Irinotecan: 150 mg/m2 IV infusion for over 1 hours • 5-FU: 400 mg/m2 IV bolus injection for over 5 minute • 5-FU: 2400 mg/m2IV continuous infusion for 46 hours every 2 weeks until progression disease or death or unacceptable toxicity 17 potential protein biomarkers, including cytokines and angiogenic factors, is chosen for analysis based on their roles in tumor progression: HGF, PIGF, VEGF-A, VEGF-C, VEGF-D, INF-r, IL-6, IL-8, Angiopoietin-2, sNeuropillin-1, TSP-2, OPN, sVEGFR1,2,3, sICAM-1, sVCAM-1, and TIMP-1 - Plasma is collected at baseline (Cycle 1) and cycle 4 - Plasma levels of the potential biomarkers are determined by enzyme-linked immunosorbent assays Primary outcome(s): Profression free survival

DISEASE(S): Neoplasms

PROVIDER: 2512693 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2614963 | ecrin-mdr-crc
| 3838 | ecrin-mdr-crc
| 2739106 | ecrin-mdr-crc
| 2623557 | ecrin-mdr-crc
| 2145885 | ecrin-mdr-crc
| 2454913 | ecrin-mdr-crc
| 2101890 | ecrin-mdr-crc
| 2640889 | ecrin-mdr-crc
| 2509659 | ecrin-mdr-crc
| 2738765 | ecrin-mdr-crc